• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

HCV Layoffs

Quote
































anonymous said:
My DM strongly feels that this Fri ER will report VPak 2q15 sales +$750M, which will exceed the $3B run rate. Hitting this number will reinforce to replace the loser reps who left.
Click to expand...

When that DM calls you in the next few weeks to let you know if you have been eliminated or not...be sure to remind him of that ridiculous comment.
 




"My DM told me", so stupid to think a DM has more information than a rep. We can read press releases, follow companies, and figure things out for ourselves. Ever heard of the Internet? "My DM told me" is a fake post from management stuck in 1990 when we had to use payphones to check voice mail. What a retro, back dated, authoritarian, Abbvie has become. Sad for you guys that are still there, no forward thinking leadership. The folks in charge don't trust their people to make good business decisions , i.e. Just do what we tell you. Terrible, toxic culture. Need to scrap leadership and start over.
 








Message to all negative posters: Eat S**T! We are kicking butt! "In Hep-C, we estimate that AbbVie can get 13-18% market share, varying by region. We now forecast WW Hep-C sales of $2.8Bn in 2016 (up from $2.5Bn) and $2.6Bn in 2017 (up from $2.3Bn) because we believe that after the TURQUOISE-III study, Viekira is more competitive in GT-1b patients."
 




anonymous said:
Message to all negative posters: Eat S**T! We are kicking butt! "In Hep-C, we estimate that AbbVie can get 13-18% market share, varying by region. We now forecast WW Hep-C sales of $2.8Bn in 2016 (up from $2.5Bn) and $2.6Bn in 2017 (up from $2.3Bn) because we believe that after the TURQUOISE-III study, Viekira is more competitive in GT-1b patients."
Click to expand...

I agree, can't wait to see earnings this Friday. VPak will blow past revenue estimates of $750M & market share +15%.
 








anonymous said:
Message to all negative posters: Eat S**T! We are kicking butt! "In Hep-C, we estimate that AbbVie can get 13-18% market share, varying by region. We now forecast WW Hep-C sales of $2.8Bn in 2016 (up from $2.5Bn) and $2.6Bn in 2017 (up from $2.3Bn) because we believe that after the TURQUOISE-III study, Viekira is more competitive in GT-1b patients."
Click to expand...

The problem with your argument is the overwhelming majority of V-Box Scripts are written because the provider was forced to use it...which means reps are not necessary...at least at the current head count levels.
 




anonymous said:
"My DM told me", so stupid to think a DM has more information than a rep. We can read press releases, follow companies, and figure things out for ourselves. Ever heard of the Internet? "My DM told me" is a fake post from management stuck in 1990 when we had to use payphones to check voice mail. What a retro, back dated, authoritarian, Abbvie has become. Sad for you guys that are still there, no forward thinking leadership. The folks in charge don't trust their people to make good business decisions , i.e. Just do what we tell you. Terrible, toxic culture. Need to scrap leadership and start over.
Click to expand...

Same dinosaurs are still running the show--c'mon what do you expect?
 




















Top Bottom
Back
Quote